Literature DB >> 9570245

Overexpression of mutant p53 and c-erbB-2 proteins and mutations of the p15 and p16 genes in human gastric carcinoma: with respect to histological subtypes and stages.

M S Wu1, C T Shun, J C Sheu, H P Wang, J T Wang, W J Lee, C J Chen, T H Wang, J T Lin.   

Abstract

Although the mechanism remains obscure, two histological subtypes of gastric carcinoma (GC), the diffuse and intestinal types, differ drastically in epidemiological, clinical, pathological and biological characteristics. We investigated whether the genetic alterations of several oncogenes and tumour suppressor genes could be correlated with the two histological subtypes. In 60 patients with GC, the overexpression of mutant p53 and c-erbB-2 oncoproteins was studied using immunohistochemical stains. Mutations of the p15 and p16 tumour suppressor genes were assessed by polymerase chain reaction, Southern blotting, and direct DNA sequencing. Overexpression of c-erbB-2 and p53 was found in 21 (35.0%) and 27 (45.0%) patients, respectively. Overexpression of the c-erbB-2 oncoprotein was more common in the intestinal type (15/32, 46.9%) and the advanced stage (19/45, 42.2%) than in the diffuse type (6/28, 21.4%) and the early stage (2/15, 13.3%) of GC (P<0.05). Similarly, p53 overexpression was more frequently found in the intestinal type (19/32, 59.4%) and the advanced stage (24/45, 53.3%) than in the diffuse type (8/28, 28.6%) and the early stage (3/15, 20.0%) of GC (P<0.05). Homozygous deletions of p16 in exon 1 were found in six (10.0%) patients. Five of them had the intestinal-type advanced GC. Neither point mutations of p16 nor alterations of p15 were detected. The frequency of alterations of p53, c-erbB-2, and p16 was not related to sex and Helicobacter pylori infection. No correlation of genetic changes between any two genes was observed. Our preliminary results indicate alterations in the p15 gene were not important in gastric tumorigenesis, while infrequent homozygous deletions in the p16 gene play a limited role in tumour progression of intestinal-type GC. Moreover, overexpression of c-erbB-2 and p53 is frequently encountered in the intestinal-type advanced GC. Alterations of p53, c-erbB-2 and p16 genes may function independently of each other in gastric carcinogenesis. The association between genetic alterations and histological subtypes supports the notion that a distinct pathogenesis may exist in different histological subtypes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9570245     DOI: 10.1111/j.1440-1746.1998.01560.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  13 in total

1.  Polymorphism of p16INK4a gene and rare mutation of p15INK4b gene exon2 in primary hepatocarcinoma.

Authors:  Yang Qin; Bo Li; Yong-Shu Tan; Zhi-Lin Sun; Feng-Qiong Zuo; Ze-Fang Sun
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

2.  Multiple genetic alterations and behavior of cellular biology in gastric cancer and other gastric mucosal lesions:H.pylori infection, histological types and staging.

Authors:  Heng-Jun Gao; Lian-Zhen Yu; Jian-Feng Bai; Yan-Shen Peng; Gu Sun; Han-Lin Zhao; Kun Miu; Xiu-Zhen L ; Xiao-Yong Zhang; Zhi-Quan Zhao
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

3.  Relationship between inactivation of p16 gene and gastric carcinoma.

Authors:  Guo-Hai Zhao; Tie-Chen Li; Liang-Hui Shi; Ya-Bin Xia; Lin-Ming Lu; Wen-Bin Huang; Hui-Lan Sun; Yi-Sheng Zhang
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

4.  Alterations of MUC1 and MUC3 expression in gastric carcinoma: relevance to patient clinicopathological features.

Authors:  R-Q Wang; D-C Fang
Journal:  J Clin Pathol       Date:  2003-05       Impact factor: 3.411

Review 5.  Pathogenetic mechanisms in gastric cancer.

Authors:  Jing Shi; Yi-Ping Qu; Peng Hou
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

6.  The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma.

Authors:  Abbas Ghaderi; Mohammad Vasei; S A Maleck-Hosseini; Behronz Gharesi-Fard; Maliheh Khodami; Mehrnoosh Doroudchi; Helmout Modjtahedi
Journal:  Pathol Oncol Res       Date:  2003-02-11       Impact factor: 3.201

7.  Methylation and mutation analysis of p16 gene in gastric cancer.

Authors:  Yi Ding; Xiao-Ping Le; Qin-Xian Zhang; Peng Du
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

8.  Neuroendocrine differentiation in gastric adenocarcinomas; correlation with tumor stage and expression of VEGF and p53.

Authors:  Funda Eren; Ciğdem Celikel; Bahadir Güllüoğlu
Journal:  Pathol Oncol Res       Date:  2004-03-18       Impact factor: 3.201

9.  p16 promoter hypermethylation: a useful serum marker for early detection of gastric cancer.

Authors:  Mohammad Reza Abbaszadegan; Omeed Moaven; Hamid Reza Sima; Kamran Ghafarzadegan; Azadeh A'rabi; Mohammad Naser Forghani; Hamid-Reza Raziee; Ali Mashhadinejad; Mostafa Jafarzadeh; Ehsan Esmaili-Shandiz; Ezzat Dadkhah
Journal:  World J Gastroenterol       Date:  2008-04-07       Impact factor: 5.742

10.  Epstein-Barr virus in gastric adenocarcinomas: association with ethnicity and CDKN2A promoter methylation.

Authors:  Q N Vo; J Geradts; M L Gulley; D A Boudreau; J C Bravo; B G Schneider
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.